Oxford Biodynamics appoints industry expert Dr Peter Pack as Non-Executive Chairman

Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitchä, announced that Dr Peter Pack, Independent Non-Executive Director, has been appointed as Independent Non-Executive Chairman of Oxford BioDynamics. Stephen Diggle, who was holding the position of Interim Chairman, will transition to the role of Non-Executive Director.  

Peter brings over 27 years of international life sciences experience to his new role. He started his career at MorphoSys AG as co-inventor of one of the most commercially successful human antibody libraries. Following this, he was co-founder and CEO of MTM laboratories AG (Heidelberg, Germany and Westborough, US), which is now part of Roche Diagnostics. During his time as CEO, Peter successfully established a fully integrated diagnostic company from scratch, developing and internationally commercialising novel, biomarker-based CINtec® tests for the screening and diagnosis of cervical cancer.

Between 2015 and 2019 he headed the Cambridge, UK-based therapeutics company Crescendo Biologics Ltd, leading its transition from a transgenic platform company to a developer of multispecific biologics with an internal, late stage preclinical pipeline in oncology. Peter has also been a board member of the transfection specialist PolyPlus (Strasbourg, France) and the biomarker company Signature Diagnostics (Potsdam, Germany) which is also now part of Roche Diagnostics.

Peter joined the OBD Board in April 2019 and in his first year as a Non-Executive Director has provided excellent support and challenge to the Executive Directors, as well as developing a deep understanding of OBD’s technology and business.

Dr Peter Pack, Non-Executive Chairman, Oxford BioDynamics, said: “It has been a pleasure to work with the Board and management team since I joined as a Non-Executive last year. The Company has grown significantly in the past few years, increasing its international footprint, its portfolio of intellectual property, and the range of global pharma and biopharma companies on its roster. This is an exciting time for OBD as we plan for further commercialisation of the EpiSwitch™ platform. I look forward to leading the Board and supporting the new CEO Jon Burrows and the rest of his team.” 

Dr Jon Burrows, CEO of Oxford BioDynamics, added: “I am delighted that Peter is taking on the role of Non-Executive Chairman. His significant commercial experience will be invaluable in his new role as Chairman and I look forward to him supporting the Company as we seek to deliver significant success for shareholders. On behalf of the whole Board, I would also like to thank Stephen Diggle for his commitment and leadership in the position of Interim Chairman over the last year and look forward to his continued membership of the Board as a Non-Executive Director.”

Stephen Diggle, Non-Executive Director, Oxford BioDynamics, said: “I’m very pleased to be stepping down as Interim Chairman to make way for Peter Pack and resume my role as a Non-Executive Director. Since joining the Board Peter has demonstrated the knowledge, acumen and judgement required to be Chairman of a company with the potential of Oxford BioDynamics.” 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,

    Oxford BioDynamics

    New questions about Covid-19

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more at risk,

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities such as

    Oxford BioDynamics

    ALS Awareness

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in response to

    Oxford BioDynamics

    ALS Awareness Month This May

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated the letters

    Oxford BioDynamics

    Microarray Facility

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of multiplex formats

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that integrate environmental

    Oxford BioDynamics

    EpiSwitch technology in Alzheimer’s disease

    Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques) outside neurons

    No more posts to show